1. The use of sodium meta arsenite in the manufacture of a pharmaceutical composition for treating non-cancer pain in a mammal. The use of claim 1, wherein the pain is visceral pain, post-surgical pain, central pain, chronic pain, or spinal pain. The use according to claim 1, wherein the pharmaceutical composition is formulated for oral administration. The use of claim 1, wherein the pharmaceutical composition comprises a metered amount of sodium meta arsenite from about 0.5 mg / kg to about 70 mg / kg. The use of claim 1, wherein the pharmaceutical composition comprises a metered amount of sodium meta arsenite from about 10 mg / kg to about 30 mg / kg. The use of claim 1, wherein the pharmaceutical composition is formulated for topical administration to a mammal. The use of claim 1, wherein the pharmaceutical composition is formulated to relieve local pain. The use of claim 1, wherein the pain is caused by herpetic neuralgia. The use of claim 1, wherein the pain is associated with diabetic neuropathy. The use of sodium meta arsenite in the manufacture of an oral dosage form for the treatment of diabetic neuropathy, diabetic vasculopathy, diabetic retinopathy or insulin-related symptoms. 11. A kit comprising at least one therapeutically effective dosage amount of sodium meta arsenite, where the amount of sodium meta arsenite is sufficient to reduce or prevent non-cancer pain in the target mammal, and optionally at least one therapeutically effective dosage amount1. Применение метаарсенита натрия в производстве фармацевтической композиции для лечения боли, не связанной с раком, у млекопитающего.2. Применение по п.1, в котором боль представляет собой висцеральную боль, постхирургическую боль, центральную боль, хроническую боль или спинальную боль.3. Применение по п.1, в котором фармацевтическая композиция составлена для орального введения.4. Применение по п.1, в котором фармацевтическая композиция содержит дозированное количество метаарсенита натрия от приблизительно
